Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Xcel Energy Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B), while Xcel Energy Inc trades at $77.66 (market cap $48.02B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.8× Xcel Energy Inc's market cap, and Xcel Energy Inc pays a 3.08% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | XEL | |
|---|---|---|
Market Cap | $132.79B | $48.02B |
Sector | Health | Utilities |
52-Week High | $529.65 | $83.91 |
52-Week Low | $376.62 | $71.75 |
Enterprise Value | $126.92B | $86.33B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Xcel Energy (XEL) trades at $78.07, up 1.43% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, driven by infrastructure investment recovery. Revenue for 2025 was $14.67B with a net income margin of 15.28%, while the balance sheet shows rising assets and liabilities, with a debt-to-asset ratio of 41.57% in 2024. Recent news highlights community investment and board additions.
The outlook for XEL is supported by a $60 billion capital plan targeting 11% annual rate base growth, but regulatory pushback and affordability concerns pose risks. Analyst consensus is bullish with a $93.80 price target, implying 20% upside, though technical indicators suggest near-term caution. Earnings growth and utility demand trends remain key catalysts for investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
